Anti-CD19 chimeric antigen receptor (CAR) T cell therapy actually represents the standard of care for multiple relapsed or refractory primary mediastinal B-cell lymphoma (r/r PMBCL). This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.